OPN1MW and schizophrenia: Following this study, a secondary exploratory double-blind parallel-group trial was conducted that examined the efficacy of CBD as an antipsychotic in patients with sub-acute schizophrenia randomised in a 1:1 ratio to receive CBD (1000 mg/day; N = 43) or placebo (N = 45) alongside their existing antipsychotic medication.